Roquefort Investments PLC (GB:ROQ) has released an update.
Roquefort Therapeutics PLC has announced a lucrative out-licensing agreement with PDC FZ-LLC, entailing an initial $10 million payment and a 24% share in future trade sale proceeds for their Midkine antibody portfolio. The deal hinges on the successful completion of Phase 1 clinical trials by PDC, which has a strong record of conducting over 150 trials. The partnership is anticipated to boost the development of Roquefort’s innovative oncology drugs and offer significant financial returns.
For further insights into GB:ROQ stock, check out TipRanks’ Stock Analysis page.
